Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Non-Current Assets (2016 - 2026)

Protara Therapeutics' Non-Current Assets history spans 14 years, with the latest figure at $51.9 million for Q1 2026.

  • Quarterly Non-Current Assets rose 23.55% to $51.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $142.7 million through Mar 2026, up 104.57% year-over-year, with the annual reading at $50.0 million for FY2025, 437.31% up from the prior year.
  • Non-Current Assets came in at $51.9 million for Q1 2026, up from $50.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $70.6 million in Q1 2022 to a low of $9.0 million in Q3 2025.
  • The 5-year median for Non-Current Assets is $11.8 million (2023), against an average of $27.5 million.
  • Year-over-year, Non-Current Assets crashed 83.29% in 2023 and then surged 437.31% in 2025.
  • Protara Therapeutics' Non-Current Assets stood at $27.1 million in 2022, then crashed by 62.24% to $10.2 million in 2023, then decreased by 9.27% to $9.3 million in 2024, then soared by 437.31% to $50.0 million in 2025, then rose by 3.93% to $51.9 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Non-Current Assets are $51.9 million (Q1 2026), $50.0 million (Q4 2025), and $9.0 million (Q3 2025).